Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$-0.47
EPS est.
$-0.47
EPS surprise
+0.00%
1-day move
-3.36%
Despite reporting record revenue, Natera's stock fell by 3.36% following the earnings announcement. The decline may reflect investor concerns despite strong growth in the oncology segment and the company's optimistic outlook. The FDA approval for Signatera and improvements in their prenatal screening test are positive developments, but the market reaction indicates caution among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.47 | N/A | +0.00% |
| Revenue | $753 million | N/A | N/A |
| Tests Processed | 1.04 million | N/A | N/A |
| Oncology Segment Growth | 56% | N/A | N/A |
| Gross Margin | 65% | N/A | N/A |
Management expressed confidence in the company's performance, highlighting record revenue and growth in key segments. They are optimistic about future prospects, especially with recent FDA approvals and enhancements to their product offerings.
Natera achieved record Q2 2026 revenue, driven by strong growth in the oncology segment.
The FDA approval for Signatera as a companion diagnostic is a significant milestone for the company.
We remain optimistic about future growth, supported by ongoing clinical trials and market adoption.
—
Est. EPS
$1.48
Est. Rev
$3.3B
Impl. Move
±16.9%
Natera, Inc. is a biotechnology company focused on genetic testing and diagnostics, particularly in reproductive health and oncology. Operating in the Health Care sector, its innovations are significant as they cater to growing demand for personalized medicine and early disease detection.
Last quarter
In Q1 2026, Natera reported an EPS of -$0.60, which was worse than the expected -$0.53, leading to a stock increase of 2.20% the next day. The company continues to face challenges in meeting earnings expectations.
EPS beat streak
0Q
EPS beat rate
38%
Avg EPS surprise
-32.20%
Avg 1-day reaction
+0.28%
Overall, investors are cautious as Natera has missed earnings expectations in recent quarters. The market will be closely watching for any signs of improvement in profitability and revenue growth.
Bull case
If Natera can show a significant reduction in losses and possibly a surprise in revenue growth, it could boost investor confidence and lead to a strong stock performance.
Bear case
Continued losses and disappointing revenue figures could lead to further declines in stock price, especially given the high expectations set by the options market.
Key metrics to watch
EPS
Expected to be around -$0.53.Earnings per share will indicate the company's profitability and how well it is managing costs.
Revenue Growth
Not available.Revenue growth is crucial for assessing the company's market demand and overall health.
The print will turn on these.
Q1
What will the EPS figure be this quarter?
Given the company's recent history of missing EPS estimates, this number will be critical in shaping investor sentiment.
Q2
How many tests were conducted in the last quarter?
Test volume is a key indicator of operational success and market demand, which will be closely scrutinized.
Why consensus could be wrong
The Street may be underestimating Natera's potential for a turnaround, as recent operational improvements could lead to better-than-expected results this quarter.
Supporting evidence
The options market is pricing a 14.15% move, suggesting that traders anticipate significant volatility.
Natera's historical performance shows that it has a 50% chance of beating EPS estimates, which could surprise the market.
The company's focus on expanding its test offerings could lead to increased revenue that is not fully reflected in current estimates.
Key risk
If test volume exceeds expectations significantly, it could shift the narrative around the company's growth potential.
Pre-commit to what would confirm each case.
The market is debating whether Natera can turn around its recent performance and show signs of growth.
Bull confirmed if
An EPS of -$0.50 or better would confirm a bullish outlook.
Bear confirmed if
An EPS worse than -$0.60 would reinforce the bearish sentiment.
What the market is pricing for the move.
Implied Move
±14.15%
Historical Avg
±1.9%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±14.2% while NTRA has averaged ±1.9% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
60.3%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.7%, with a raw directional average of -1.5% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
96.75%
of float
Insider
2.74%
of float
Holders
1,196
institutions
Top Holders· as of Jun 2026
JPMORGAN CHASE & CO
12,865,346 sh · $5.1B
8.93%
-3.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Natera beats expectations, history suggests a potential stock increase of around 1.81%, confirming a positive trend.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
Should the company miss expectations, history suggests a possible decline of around 1.41%, reflecting continued investor concerns.
The lines on the call that would change the story.
Test Volume
Not available.The number of tests conducted can provide insight into operational efficiency and market penetration.
Blackrock Inc.
10,914,608 sh · $4.3B
7.57%
2.2%
Price (T.Rowe) Associates Inc
9,021,895 sh · $3.6B
6.26%
-26.0%
Vanguard Capital Management LLC
6,228,216 sh · $2.5B
4.32%
3.7%
Vanguard Portfolio Management LLC
5,782,640 sh · $2.3B
4.01%
2.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.